12th International Workshop on Ataxia-Telangiectasia and ATM

第十二届共济失调毛细血管扩张与 ATM 国际研讨会

基本信息

  • 批准号:
    7163680
  • 负责人:
  • 金额:
    $ 1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-01 至 2007-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ataxia-telangiectasia (A-T) is a rare autosomal recessive disorder that affects approximately 1 in 40,000 to 1 in 100,000 live births. A-T is characterized by progressive cerebellar ataxia, telangiectasia, immunodeficiency, chromosomal instability, radiation sensitivity and increased incidence of lymphoid malignancies. Symptoms of A-T usually manifest in the first few years of life when children exhibit wobbly gait. Loss of neuromuscular control is relentless and, by their teens, children are usually confined to a wheel chair. A-T patients usually succumb to infection and/or lymphoma in the second decade of life. In addition, it has been estimated that up to 1% of the general population carries mutations in one allele of the ATM (ataxia-telangiectasia mutated) gene and ATM heterozygotes have an increased risk of developing breast cancer. The ATM gene encodes a large (369 kDa) protein, ATM, that is a member of the phosphatidyl inositol 3 kinase family of serine threonine protein kinases (the PIKKs). Cells that lack ATM are highly sensitive to ionizing radiation (IR) and are defective in the activation of multiple cell cycle checkpoints in response to IR and other DNA damaging agents. Since the discovery of the gene in 1995, it has become apparent that ATM plays a critical role in regulating the cellular response to IR and other DNA damaging agents. Understanding the function of ATM is of considerable importance to understanding the etiology of the disease, the molecular basis for increased cancer predisposition in A-T patients and ATM heterozygotes, and the molecular mechanisms that control how cells respond to radiotherapy and many chemotherapeutic drugs. In this application, funds are requested for partial support towards the 12th International Workshop on Ataxia-Telangiectasia and ATM, which will be held at the Banff Centre, Banff, Alberta, Canada, September 8th to 12th 2006. Objectives of the meeting: The objectives of the meeting are to bring together basic and clinical researchers working on various aspects of the clinical features of A-T, the role of ATM in the DNA damage response, and the role of ATM in the nervous system, in an informal but stimulating scientific atmosphere which will promote scientific interactions, discussions and research collaborations into understanding the functions of ATM and the biological basis of A-T. Our goal is to stimulate research that will lead to better understanding of and treatments for A-T. Specific areas of focus of the meeting will include the role of ATM and related proteins in the DNA damage response, the importance of chromatin in the activation of ATM, the role of ATM in the nervous system, mechanisms of neurodegeneration, the role of other DNA damage proteins in neuropathies, animal models of A-T, ATM in breast and other human cancers, epidemiology of ATM mutations, towards the development of new treatments for A-T, and an update on clinical trials for A-T.
描述(申请人提供):共济失调-毛细血管扩张症(A-T)是一种罕见的常染色体隐性遗传病,大约每40,000到100,000名活产儿中就有1人患病。A-T的特点是进行性小脑性共济失调、毛细血管扩张、免疫缺陷、染色体不稳定、辐射敏感和淋巴系统恶性肿瘤发病率增加。A-T的症状通常在生命的最初几年表现出来,此时儿童表现出步态不稳。神经肌肉控制的丧失是无情的,到了十几岁,孩子们通常被限制在轮椅上。A-T患者通常在第二个十年死于感染和/或淋巴瘤。此外,据估计,高达1%的普通人群携带ATM(共济失调-毛细血管扩张突变)基因的一个等位基因突变,ATM杂合子患乳腺癌的风险增加。ATM基因编码一个大的(369 KDa)蛋白ATM,它是丝氨酸苏氨酸蛋白激酶(PIKKs)的磷脂酰肌醇3激酶家族的成员。缺乏ATM的细胞对电离辐射(IR)高度敏感,并且在响应IR和其他DNA损伤剂的多个细胞周期检查点的激活方面存在缺陷。自从1995年发现该基因以来,ATM在调节细胞对IR和其他DNA损伤剂的反应中发挥着至关重要的作用。了解ATM的功能对于了解疾病的病因、A-T患者和ATM杂合子增加癌症易感性的分子基础以及控制细胞对放射治疗和许多化疗药物的反应的分子机制具有相当重要的意义。在这项申请中,请拨资金用于为2006年9月8日至12日在加拿大艾伯塔省班夫中心举行的第12届共济失调-毛细血管扩张症和ATM国际研讨会提供部分支助。会议目的:会议的目的是在非正式但具有启发性的科学氛围中,汇聚致力于A-T的临床特征、ATM在DNA损伤反应中的作用以及ATM在神经系统中的作用的基础和临床研究人员,以促进科学互动、讨论和研究合作,以了解ATM的功能和A-T的生物学基础。我们的目标是促进研究,从而更好地了解和治疗动静脉曲张。会议的重点领域包括ATM和相关蛋白质在DNA损伤反应中的作用,染色质在ATM激活中的重要性,ATM在神经系统中的作用,神经退变的机制,其他DNA损伤蛋白在神经疾病中的作用,A-T的动物模型,ATM在乳腺癌和其他人类癌症中的作用,ATM突变的流行病学,A-T的新治疗方法的开发,以及A-T的临床试验的最新进展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD A GATTI其他文献

RICHARD A GATTI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD A GATTI', 18)}}的其他基金

14th International Workshop on Ataxia-Telangiectasia and ATM
第14届共济失调毛细血管扩张与ATM国际研讨会
  • 批准号:
    7805688
  • 财政年份:
    2010
  • 资助金额:
    $ 1万
  • 项目类别:
Pilot Projects Core
试点项目核心
  • 批准号:
    8011757
  • 财政年份:
    2010
  • 资助金额:
    $ 1万
  • 项目类别:
13th International Workshop on Ataxia-Telangiectasia and ATM
第13届共济失调-毛细血管扩张与ATM国际研讨会
  • 批准号:
    7483575
  • 财政年份:
    2008
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    7640833
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    8094618
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    7874551
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    8090432
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    7316730
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    7681871
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:
DRUG-INDUCED ATM READTHROUGH OF PTC MUTATIONS
药物诱导的 ATM 读取 PTC 突变
  • 批准号:
    7488560
  • 财政年份:
    2007
  • 资助金额:
    $ 1万
  • 项目类别:

相似海外基金

Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by exploiting SIMilarities in clinical and molecular PATHology
利用临床和分子病理学的相似性,加速罕见神经系统、神经代谢和神经肌肉疾病的药物再利用
  • 批准号:
    10077172
  • 财政年份:
    2023
  • 资助金额:
    $ 1万
  • 项目类别:
    EU-Funded
Molecular pathology investigation for targeted therapy of intractable pediatric epilepsy via mTOR pathway hyperactivation
mTOR通路过度激活靶向治疗顽固性小儿癫痫的分子病理学研究
  • 批准号:
    23K07339
  • 财政年份:
    2023
  • 资助金额:
    $ 1万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CORE B (Molecular Pathology Core)
CORE B(分子病理学核心)
  • 批准号:
    10662327
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
Molecular pathology in special type of colonic adenocarcinoma
特殊类型结肠腺癌的分子病理学
  • 批准号:
    22K15430
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigating the molecular pathology of WDR26 deficiency
研究 WDR26 缺陷的分子病理学
  • 批准号:
    472604
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
    Operating Grants
CORE B (Molecular Pathology Core)
CORE B(分子病理学核心)
  • 批准号:
    10407749
  • 财政年份:
    2022
  • 资助金额:
    $ 1万
  • 项目类别:
Cell-type-specific molecular pathology of ALS in U.S. military Veterans
美国退伍军人 ALS 的细胞类型特异性分子病理学
  • 批准号:
    10254543
  • 财政年份:
    2021
  • 资助金额:
    $ 1万
  • 项目类别:
Unraveling the molecular pathology of retinal degeneration through single cell genomics
通过单细胞基因组学揭示视网膜变性的分子病理学
  • 批准号:
    10211475
  • 财政年份:
    2021
  • 资助金额:
    $ 1万
  • 项目类别:
Cell-type-specific molecular pathology of ALS in U.S. military Veterans
美国退伍军人 ALS 的细胞类型特异性分子病理学
  • 批准号:
    10513300
  • 财政年份:
    2021
  • 资助金额:
    $ 1万
  • 项目类别:
Translating molecular pathology into cancer diagnostics
将分子病理学转化为癌症诊断
  • 批准号:
    nhmrc : 1193630
  • 财政年份:
    2021
  • 资助金额:
    $ 1万
  • 项目类别:
    Investigator Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了